PetCaseFinder

Peer-reviewed veterinary case report

Urinary cystatin B test for acute kidney injury in cats

By Chen, Hilla et al.·Published in Veterinary journal (London, England : 1997)·2024·Veterinary Teaching Hospital·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Urinary Cystatin B as a marker of acute kidney injury in cats.

Species:
cat

Plain-English summary

A group of cats with acute kidney injury (AKI) was studied to see if a urine test for a substance called Cystatin B could help diagnose and predict outcomes. The results showed that cats with AKI had significantly higher levels of Cystatin B in their urine compared to healthy cats and those with chronic kidney disease. This test was found to be very accurate, with a high sensitivity and specificity, meaning it could reliably identify cats with AKI. The study suggests that measuring Cystatin B could be a valuable tool for veterinarians in diagnosing and managing kidney issues in cats.

People also search for: cat acute kidney injury symptoms · cat kidney disease urine test · Cystatin B in cats

Abstract

Diagnosing acute kidney injury (AKI) might be challenging due to lack of sensitive early markers. The objective of this study was to evaluate the diagnostic and prognostic utility of the urinary biomarker Cystatin B (uCysB) in cats with AKI. Seventy-six client-owned cats were included. Urine samples of healthy cats and cats with various urinary tract disease including urethral obstruction (UO), chronic kidney disease (CKD) and AKI, were collected. uCysB concentration was measured using a research sandwich format ELISA at IDEXX Laboratories, Inc. uCysB was different among groups (P <0.001). uCysB was higher in the AKI (P <0.001) and CKD (P =0.006) groups compared with controls [1052&#x202f;ng/mL (range, 7-3858) and 112&#x202f;ng/mL (range, 14-1370) vs. 22&#x202f;ng/mL (range, 11-154), respectively]. Cats with AKI had higher uCysB compared with cats with CKD (P =0.001) or UO (P =0.004). Receiver operator characteristic curve (ROC) analysis of uCysB as an AKI predictor vs. controls had an area under the curve (AUC) of 0.92 (95&#x202f;%&#xa0;CI, 0.84-1.0). An 84&#x202f;ng/mL cutoff point corresponded to sensitivity and specificity of 90&#x202f;% and 92&#x202f;%, respectively. uCysB concentration was higher in AKI non-survivors compared with survivors (1572&#x202f;ng/mL, range, 140-3858 vs. 584&#x202f;ng/mL, range, 7-2803 respectively; P =0.004). ROC analysis of uCysB as an AKI outcome predictor had an AUC of 0.84 (95&#x202f;%&#xa0;CI, 0.56-1.0), with an optimal cut-off point of 469&#x202f;ng/mL, corresponding to sensitivity and specificity of 100&#x202f;% and 75&#x202f;% respectively. In conclusion, uCysB is a useful diagnostic and prognostic marker of AKI in cats.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39486474/